dsgn: the income statement

MyFinsight

Design Therapeutics, Inc. (DSGN)

For the quarter ending 2025-06-30, DSGN made $2,486K in revenue. -$19,083K in net income. Net profit margin of -767.62%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

	2025-06-30
Research and development (including related party amounts of 230, 222, 458 and 446, respectively)	15,738
General and administrative (including related party amounts of 131, 136, 265 and 271, respectively)	5,831
Total operating expenses	21,569
Loss from operations	-21,569
Interest income	2,486
Net loss	-19,083

Net loss per share, basic	-0.34
Net loss per share, diluted	-0.34
Weighted-average shares of common stock outstanding, basic	56,859,388
Weighted-average shares of common stock outstanding, diluted	56,859,388

Unit: Thousand (K) dollars (except for numbers of shares and EPS)